⌕
DBV Technologies · DBVT · Nasdaq
Tenet 31 · Weak
Compare
$9.42−2.69%At closeTenet 31 · Weak
$9.42−0.26 (−2.69%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD

DBV Technologies (DBVT) Stock

DBV Technologies (DBVT) closed at $9.42 on Nov 19, 2026; its Tenet Score is 31 of 100 against 487 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

Key stats

Close
$9.42
Nov 19, 2026
Market cap
$592.3M
share price × the latest quarter's diluted weighted-average share count (vendor)
Dividend yield
0.00%
reinvests all
52-week range
8.63 – 26.18
low → high
Tenet Score
31/100
Weak · 487 Healthcare peers

Industry: Drugs · see every company filed here →

DBV Technologies scores 31/100. Weak. Growth is the soft spot versus 487 Healthcare peers.

Tenet Score · vs sector

n=487
31/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
45
Quality
16
Health
56
Growth
7

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueDQualityFHealthCGrowthFMomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not reported in the company's filings for this period.
P/B
4.0×
cap ÷ Sep 30, 2026 book value, Nov 19, 2026 close
P/S
105.1×
price to sales
ROE
−206%
TTM through Sep 30, 2026
Operating margin
−2609.2%
fiscal 2025, before interest and tax
Net margin
—
Not reported in the company's filings for this period.
Current ratio
3.24
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.

The whole report, at a glance · every card is a live peek, click any to open the section

About DBV Technologies

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical…

Composite computed Nov 20, 2026 · peer basis: Healthcare (n=487) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 1 US ETFs · top wrappers by weightSee all ETFs holding DBVT →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is DBV Technologies in?

DBV Technologies is in the Healthcare sector and the Drugs industry.

What is DBV Technologies' Tenet Score?

DBV Technologies' Tenet Score is 31 out of 100, ranked against 487 Healthcare peers as of Nov 20, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.